FrancophonIA/ELRC3.0 huggingface dataset:
English: In accordance with the PRAC recommendation, in order to evaluate the recurrence of hepatocellular carcinoma associated with direct-acting antivirals, the MAHs shall conduct and submit the results of a prospective safety study using data deriving from a cohort of a well-defined group of patients, based on an agreed protocol setting out criteria for entry and follow-up of patients in terms of timing and
Estonian: Vastavalt ravimiohutuse riskihindamise komitee soovitusele peavad müügiloa hoidjad otsese toimega viirusevastaste ainetega seotud hepatotsellulaarse kartsinoomi kordumise riski hindamiseks tegema ettevaatava ohutusuuringu ja esitama selle tulemused, kasutades täpselt määratletud patsientide rühma kohordist saadud andmeid, mis põhinevad kokkulepitud protokollil, kus kehtestatakse patsientide osalemise ja järelkontrolli kriteeriumid seoses tähtaegade ja sõelumismeetodiga.
English: In addition, interim results should be submitted for PRAC assessment by Q4 2019.
Estonian: Lisaks tuleb 2019. aasta neljandas kvartalis esitada ravimiohutuse riskihindamise komiteele
English: Having reviewed the PRAC recommendation, the CHMP agreed with the overall scientific conclusions
Estonian: Inimravimite komitee arvamus ja üksikasjalikud selgitused ravimiohutuse riskihindamise komitee soovitusest lahknevuse teaduslike aluste kohta Olles tutvunud ravimiohutuse riskihindamise komitee soovitusega, nõustus inimravimite komitee üldiste teaduslike järeldustega ja soovituse alustega.
English: EU/1/17/1226/001 LUTATHERA 370 MBq/ml
Estonian: EU/1/17/1226/001 LUTATHERA
English: Solution for infusion
Estonian: Infusioonilahus
English: MA (EU) number (Invented) name
Estonian: (Väljamõeldud)
English: 1 ml (100 mg/ml) 3 (3 x 1) prefilled syringes (multipack)
Estonian: 3 (3 x 1) süstlit (mitmikpakend)
English: MA (EU) number
Estonian: Müügiloa number Euroopa Liidus
English: 1 ml (100 mg/ml) 3 (3 x 1) prefilled pens (multipack)
Estonian: 3 (3 x 1) pen-süstlit (mitmikpakend)
English: 23 May 2013
Estonian: 23. mai 2013
English: International non-proprietary name (INN): florfenicol
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): florfenikool
English: The opinion was converted into a Decision by the European Commission on 23 May 2013.
Estonian: Arvamus kinnitati Euroopa Komisjoni otsusena 23. mail 2013.
English: Written explanations were provided by the applicant on 11 September 2012 and 9 January 2013.
Estonian: Taotleja esitas kirjalikud selgitused 11. septembril 2012 ja 9. jaanuaril 2013.
English: The decentralised procedure started on 17 December 2010.
Estonian: Detsentraliseeritud menetlus algas 17. detsembril 2010.
English: Oral explanations were given on 5 March 2013.
Estonian: Suulised selgitused esitati 5. märtsil 2013.
English: Florgane 300 mg/ml suspension for injection has been authorised for use in cattle as a hybrid of Nuflor 300 mg/ml solution for injection using the decentralised procedure (DE/V/0132/001/DC) with Germany as a reference Member State and Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Greece, Hungary, Ireland, Italy, Lithuania, Luxemburg, the Netherlands, Poland, Portugal, Romania, Slovakia, Spain and the United Kingdom as concerned Member States.
Estonian: Florgane 300 mg/ml süstesuspensioon kiideti veistel kasutamiseks heaks Nuflor 300 mg/ml süstelahuse hübriidravimina detsentraliseeritud menetluse (DE/V/0132/001/DC) kaudu, kus viiteliikmesriik oli Saksamaa ning asjaomased liikmesriigid Austria, Belgia, Bulgaaria, Hispaania, Iirimaa, Itaalia, Kreeka, Leedu, Luksemburg, Madalmaad, Poola, Portugal, Prantsusmaa, Rumeenia, Slovakkia, Taani, Tšehhi Vabariik, Ungari, Ühendkuningriik.
English: The Committee appointed Prof. Christian Friis as rapporteur and Dr Cornelia Ibrahim as co-rapporteur.
Estonian: Veterinaarravimite komitee määras hindajaks prof Christian Friisi ja kaashindajaks dr Cornelia Ibrahimi.
English: The referral procedure started on 15 May 2012.
Estonian: Esildise menetlemine algas 15. mail 2012.
English: The reference product was Nuflor Swine Injectable Solution 300 mg/ml (FR/V/0118/001).
Estonian: Võrdlusravim oli Nuflor Swine 300 mg/ml süstelahus (FR/V/0118/001).
English: Potential serious risks were identified during the decentralised procedure by Denmark regarding the efficacy of the product and the potential for development of antimicrobial resistance to florfenicol.
Estonian: Detsentraliseeritud menetluse ajal teatas Taani võimalikest rasketest riskidest, mis olid seotud ravimi efektiivsusega ja võimaliku ravimiresistentsuse tekkimisega florfenikooli suhtes.
English: On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 20 February 2012.
Estonian: Menetluse 210. päeval olid need küsimused lahendamata ning seetõttu tehti 20. veebruaril 2012 veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluse koordineerimisrühmale direktiivi 2001/82/EÜ artikli 33 lõike 1 kohane esildis.
English: Florfenicol is structurally related to thiamphenicol and has a similar pharmacological profile.
Estonian: Florfenikool sarnaneb struktuuri poolest tiamfenikooliga ja nende farmakoloogiline profiil on samalaadne.
English: The proposed dose is 22.5 mg florfenicol per kg bodyweight given by intramuscular administration as a single injection.
Estonian: Ravimi kavandatav annus on 22,5 mg florfenikooli kg kehamassi kohta, mis manustatakse ühe intramuskulaarse süstina.
English: This extension application (DE/V/0132/001/DX/001) was submitted according to the same procedure (DCP) and type of application (hybrid, according to Article 13(3) of Directive 2001/82/EC) as for the initial application for cattle, to the same Member States.
Estonian: Müügiloa laiendamise taotlus (DE/V/0132/001/DX/001) esitati sama muudetud direktiivi 2001/82/EÜ artikli 13 lõike 3 kohase detsentraliseeritud menetluse ja taotluse (hübriid) kaudu ülalmainitud liikmesriikidele nagu esialgne taotlus veiste kohta.
English: Day 60 of the CMD(v) procedure was on 19 April 2012, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP.
Estonian: Koordineerimisrühma menetluse 60. päev oli 19. aprill 2012 ning et asjaomased liikmesriigid ei jõudnud ravimi osas üksmeelele, tehti esildis veterinaarravimite komiteele.
English: Opinion following an Article 33(4)0F referral for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names EMA/324042/2013
Estonian: Arvamus pärast artikli 33 lõike 40F kohast esildist Florgane 300 mg/ml süstesuspensioon veistele ja sigadele ja sarnased nimetused EMA/324042/2013
English: On 19 April 2012, the reference Member State, Germany, notified to the European Medicines Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC.
Estonian: 19. aprillil 2012 teatas viiteliikmesriik Saksamaa Euroopa Ravimiametile, et veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste koordineerimisrühm ei saavutanud ravimi suhtes üksmeelt ning tegi veterinaarravimite komiteele direktiivi 2001/82/EÜ artikli 33 lõike 4 kohase esildise.
English: Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Florgane 300 mg/ml suspension for injection for cattle and pigs is positive.
Estonian: Olemasolevate andmete hindamise alusel leidis veterinaarravimite komitee, et ravimi Florgane 300 mg/ml süstesuspensioon veistele ja sigadele kasulikkuse ja riski profiil on positiivne.
English: Therefore, the Committee adopted by majority a positive opinion on 6 March 2013 recommending the granting of a marketing authorisation for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names.
Estonian: Seetõttu võttis veterinaarravimite komitee 6. märtsil 2013 häälteenamusega vastu positiivse arvamuse, soovitades anda veistele ja sigadele ettenähtud süstesuspensiooni Florgane 300 mg/ml ja sarnaste nimetuste müügiloa.
English: Florgane 300 mg/ml suspension for injection for cattle and pigs contains florfenicol as active ingredient and is intended for use in pigs for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae and Pasteurella multocida susceptible to florfenicol.
Estonian: Veterinaarravimit kavatseti sigadel kasutada florfenikooli suhtes tundlike bakterite Actinobacillus pleuropneumoniae ja Pasteurella multocida tüvedest põhjustatud hingamisteede infektsioonide ägedate puhangute raviks.
English: The applicant, Emdoka bvba, submitted an application for a decentralised procedure for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names.
Estonian: Taotleja Emdoka bvba esitas veistele ja sigadele ettenähtud süstesuspensiooni Florgane 300 mg/ml ja sarnaste nimetuste detsentraliseeritud menetluse taotluse, millega soovitakse laiendada veistel kasutamiseks heakskiidetud florfenikooli 300 mg/ml süstesuspensiooni müügiluba ravimi kasutamiseks sigadel.
English: Opinion following an Article 33(4)1 referral for Florgane 300 mg/ml suspension for injection for cattle and pigs and associated names
Estonian: Florgane 300 mg/ml süstesuspensioon veistele ja sigadele ja sarnased nimetused
English: It is available as tablets (300 mg/150 mg/300 mg).
Estonian: Seda turustatakse tablettidena (300 mg/150 mg/300 mg).
English: No specific clinical studies have been carried out to assess the safety and effectiveness of the combined tablet.
Estonian: Kombineeritud tableti ohutuse ja efektiivsuse hindamiseks ei ole tehtud spetsiaalseid kliinilisi uuringuid.
English: The recommended dose of Trizivir is one tablet twice a day.
Estonian: Triziviri soovitatav annus on üks tablett kaks korda ööpäevas.
English: A risk management plan has been developed to ensure that Trizivir is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Triziviri võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the EU for Trizivir on 28 December 2000.
Estonian: Euroopa Komisjon andis Triziviri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. detsembril 2000.
English: The full EPAR for Trizivir can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Triziviri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Trizivir?
Estonian: Mis meetmed võetakse, et tagada Triziviri ohutu ja efektiivne kasutamine?
English: All three active substances have been available in the European Union (EU) for a number of years: abacavir has been authorised as Ziagen since 1999, lamivudine has been authorised as Epivir since 1996, and zidovudine has been available in the EU since the mid-1980s.
Estonian: Kõiki kolme toimeainet on Euroopa Liidus turustatud aastaid: abakaviiril on müügiluba ravimina Ziagen alates 1999. aastast, lamivudiinil ravimina Epivir alates 1996. aastast ja sidovudiini on turustatud Euroopa Liidus alates 1980. aastate keskpaigast.
English: Trizivir does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Trizivir ei ravi HIV-nakkust ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ja AIDSiga seotud nakkuste ja haiguste teket edasi lükata.
English: It also noted that the benefit of Trizivir has mainly been shown in patients who have had little or no previous HIV treatment and who do not have advanced disease.
Estonian: Komitee märkis ka, et Triziviri kasulikkus on tõendatud peamiselt patsientidel, kes ei ole varem HIV-ravi saanud või on saanud seda vähe ja kelle haigus ei ole süvenenud.
English: In patients with high levels of HIV in the blood (above 100,000 copies/ml), the choice of treatment requires special consideration.
Estonian: Patsientidele, kelle vere HIV-sisaldus on suur (üle 100 000 koopia/ml), tohib ravi määrata alles pärast hoolikat kaalutlemist.
English: Trizivir reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Trizivir vähendab HIVi sisaldust veres ja hoiab selle sisalduse väikese.
English: Overall, since certain other combination treatments could be more effective, the use of Trizivir should only be considered under special circumstances such as co-infection with tuberculosis (as other HIV treatments can interact with the medicines being taken by the patient).
Estonian: Et teatud muud kombineeritud ravimid võivad olla efektiivsemad, tuleb Triziviri määrata üksnes erijuhtudel, näiteks kaasuva tuberkuloosinakkuse korral (muudel HIV-ravimitel võib olla koostoimeid patsiendi võetavate ravimitega).
English: The combination tablet was absorbed in the body in the same way as the separate tablets.
Estonian: Kombineeritud tablett imendus organismis samamoodi kui eraldi tabletid.
English: The risk of hypersensitivity is higher in patients who have the HLA-B (type 5701) gene.
Estonian: Ülitundlikkuse risk on suurem patsientidel, kellel on geeni HLA-B tüüp 5701.
English: Trizivir abacavir, lamivudine and zidovudine
Estonian: Trizivir abakaviir, lamivudiin ja sidovudiin
English: Patients should have been taking the three active substances separately for at least six to eight weeks before switching to Trizivir.
Estonian: Enne üleminekut Trizivirile peavad patsiendid olema kasutanud nimetatud kolme toimeainet eraldi vähemalt 6-8 nädalat.
English: The Committee decided that Trizivir's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Triziviri kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: The company also looked at the way the combined tablet was absorbed in the body in comparison with the separate tablets.
Estonian: Ettevõte uuris ka kombineeritud tableti imendumist organismis, võrreldes seda eraldi tablettide imendumisega.
English: The most common effects with Trizivir (seen in more than 1 patient in 10) are headache and nausea (feeling sick).
Estonian: Triziviri kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peavalu ja iiveldus.
English: Other information about Trizivir:
Estonian: Muu teave Triziviri kohta
English: Symptoms almost always include fever or rash, but also very commonly include nausea, vomiting, diarrhoea, abdominal pain (stomach ache), headache, signs of liver damage in the blood, myalgia (muscle pain), dyspnoea (difficulty breathing), cough, lethargy
Estonian: Peaaegu alati on sümptomiteks palavik või lööve, kuid väga sageli ka iiveldus, oksendamine, kõhulahtisus, kõhuvalu, peavalu, maksakahjustuste nähud veres, müalgia (lihasevalu), düspnoe (hingamisraskused), köha, loidus ja halb enesetunne.
English: Patients with this gene are at an increased risk of having an allergic reaction to abacavir so they should not take Trizivir.
Estonian: Selle geeniga patsientidel on abakaviiri suhtes suur allergiareaktsiooni risk, seega ei tohi nad Triziviri võtta.
English: In the studies carried out for the development of Ziagen, the combination of the three active substances was shown to be at least as effective as the comparator combinations in keeping viral loads low.
Estonian: Ziageni väljatöötamise ajal tehtud uuringutes leiti, et kolm toimeainet koos hoiavad viiruskoormuse väiksena vähemalt sama efektiivselt kui nendega võrreldud ravimikombinatsioonid.
English: Trizivir must not be used in patients who have kidney failure.
Estonian: Triziviri ei tohi kasutada ka patsiendid, kellel on neerupuudulikkus.
English: Patients will also receive an alert card summarising key safety information on hypersensitivity reactions with this medicine.
Estonian: Samuti saavad patsiendid hoiatuskaardi, milles on ülitundlikkusreaktsiooni kokkuvõtlik ohutusteave.
English: In addition, the company that markets Trizivir provides educational materials for doctors about hypersensitivity reactions with the medicine, including the need to test patients for the HLA-B (type 5701) gene and to remind patients to contact their doctor immediately if they develop symptoms suggestive of hypersensitivity.
Estonian: Lisaks annab Triziviri turustaja arstidele ravimi ülitundlikkusreaktsioonide kohta teabematerjalid, milles on rõhutatud, et patsientidel tuleb kontrollida geeni HLA-B tüübi 5701 olemasolu ja et neile tuleb meenutada, et nad pöörduksid ülitundlikkusnähtude ilmnemisel otsekohe arsti poole.
English: For more information about treatment with Trizivir, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Triziviriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Trizivir is a medicine that contains three active substances: abacavir, lamivudine and zidovudine.
Estonian: Trizivir on ravim, mis sisaldab kolme toimeainet: abakaviiri, lamivudiini ja sidovudiini.
English: Treatment with Trizivir should be started by a doctor who has experience in the management of HIV infection.
Estonian: Ravi Triziviriga peab alustama HIV-nakkuse ravis kogenud arst.
English: This document is a summary of the European Public Assessment Report (EPAR) for Trizivir.
Estonian: See on ravimi Trizivir Euroopa avaliku hindamisaruande kokkuvõte.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Trizivir, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Triziviri omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Because it contains zidovudine, Trizivir must not be used by patients with low neutrophil counts (low levels of a type of white blood cell) or anaemia (low red blood cell counts).
Estonian: Sidovudiini sisalduse tõttu ei tohi Triziviri kasutada patsiendid, kellel on neutrofiilide (vere teatud valgelibled) väike sisaldus või aneemia (erütrotsüütide ehk vere punaliblede vähesus).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Trizivir.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the full list of all side effects reported with Trizivir, see the package leaflet.
Estonian: Triziviri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Before prescribing Trizivir, doctors should consider the expected improved ability of the patient to stick to their treatment, the expected effectiveness of the medicine, and the risks associated with the active substances.
Estonian: Arst peab enne Triziviri-ravi määramist arvestama, et patsient eeldatavasti järgib raviskeemi paremini, samuti ravimi eeldatavat efektiivsust ja toimeainete riske.
English: The company presented the results of studies with abacavir, lamivudine and zidovudine taken together, which were carried out during the development of Ziagen.
Estonian: Ettevõte esitas Ziageni väljatöötamise ajal tehtud abakaviiri, lamivudiini ja sidovudiini koosmanustamise uuringute tulemused.
English: Hypersensitivity reactions (allergic reactions) occur in patients taking Trizivir, usually within the first six weeks of treatment, and can be life-threatening.
Estonian: Triziviri kasutavatel patsientide esineb (tavaliselt esimese 6 ravinädala jooksul) ülitundlikkusreaktsioone (allergiareaktsioone) ja need võivad olla eluohtlikud.
English: If patients need to stop taking abacavir, lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing abacavir, lamivudine or zidovudine separately.
Estonian: Kui patsientidel on vaja neeru-, maksavõi verehäirete tõttu katkestada kas abakaviiri, lamivudiini või sidovudiini kasutamine või nende annust muuta, peavad nad võtma abakaviiri, lamivudiini või sidovudiini sisaldavaid ravimeid eraldi.
English: Why has Trizivir been approved?
Estonian: Miks Trizivir heaks kiideti?
English: What is the risk associated with Trizivir?
Estonian: Mis riskid Triziviriga kaasnevad?
English: Trizivir is used to treat adults who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Triziviri kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese immuunpuudulikkuse viiruse (HIV) nakkuse raviks täiskasvanutel.
English: What is Trizivir?
Estonian: Mis on Trizivir?
English: Before starting treatment with abacavir, all patients should have a test to find out if they have a gene called ‘HLA-B (type 5701)'.
Estonian: Enne abakaviiriga toimuva ravi algust tuleb uurida, kas patsiendil on geeni HLA-B tüüp 5701.
English: It is used to replace treatment with the three active substances (abacavir, lamivudine and zidovudine) taken separately at doses similar to those in Trizivir.
Estonian: Trizivir asendab ravi kolme eri toimeainega (abakaviiri, lamivudiini ja sidovudiiniga), mida võetakse eraldi, Triziviriga sarnastes annustes.
English: The CHMP noted that the reduction in the number of tablets that patients need to take may help patients stick to their treatment.
Estonian: Inimravimite komitee märkis, et tänu võetavate tablettide väiksemale arvule on kergem järgida ravirežiimi.
English: All three active substances in Trizivir, abacavir, lamivudine, and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
Estonian: Triziviri kolm toimeainet abakaviir, lamivudiin ja sidovudiin on nukleosiidsed pöördtranskriptaasi inhibiitorid, mis blokeerivad ensüümi pöördtranskriptaasi toime.
English: How is Trizivir used?
Estonian: Kuidas Triziviri kasutatakse?
English: What benefit has Trizivir shown during the studies?
Estonian: Milles seisneb uuringute põhjal Triziviri kasulikkus?
English: Treatment with Trizivir should be stopped promptly if the patient has a hypersensitivity reaction.
Estonian: Kui patsiendil tekib ülitundlikkusreaktsioon, tuleb ravi Triziviriga katkestada otsekohe.
English: What is Trizivir used for?
Estonian: Milleks Triziviri kasutatakse?
English: How has Trizivir been studied?
Estonian: Kuidas Triziviri uuriti?
English: They all work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Estonian: See HIVi tekitatav ensüüm võimaldab viirusel nakatunud rakkudes paljuneda.
English: The medicine can only be obtained with a prescription.
Estonian: Trizivir on retseptiravim.
English: How does Trizivir work?
Estonian: Kuidas Trizivir toimib?
English: MA (EU) number (Invented) name Strength Pharmaceutical Form
Estonian: Ravimvorm Manustamistee Sisepakendi iseloomustus
English: Repeatability was 97%.
Estonian: Korratavus oli 97%.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/18/1337/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/18/1337/001
English: Package leaflet: Information for the patient/user
Estonian: Pakendi infoleht: teave patsiendile/kasutajale
English: In the event of an overdose, symptomatic and supportive measures should be employed.
Estonian: Üleannustamise korral tuleb kasutada sümptomaatilisi ja toetavaid meetmeid.
English: Agreement between the result of the first test and the second test was observed in 31 cases (91.2%).
Estonian: Esimese testi ja teise testi tulemuse vastavust täheldati 31 juhul (91,2%).
English: To ensure that the test results are reliable, you need to follow the rules below:
Estonian: Et tagada testi tulemuste usaldusväärsus, peate järgima alltoodud reegleid: